OOIR: Observatory of International Research

Papers

(The TQCC of Current Opinion in HIV and AIDS is 6. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)

Article	Citations
Updates on bone health in people living with HIV: global impact, prediction tools, and treatment	103
Future options for long-acting HIV treatment and prevention	73
Editorial introductions	50
Recent advances on anti-HIV chimeric antigen receptor-T-cell treatment to provide sustained HIV remission	38
The sounds of silencing: dynamic epigenetic control of HIV latency	31
Statins for primary cardiovascular disease prevention among people with HIV: emergent directions	29
HIV-associated tuberculosis in infants, children, and adolescents younger than 15 years: an update on the epidemiology, diagnosis, prevention, and treatment	26
Harnessing natural killer cells to target HIV-1 persistence	26
Impact of early antiretroviral therapy, early life immunity and immune sex differences on HIV disease and posttreatment control in children	26
Advancing HIV cure: insights from developing chronic hepatitis b therapies for functional cure	25
Editorial introduction	24
New latency-promoting agents for a block-and-lock functional cure strategy	24
Loneliness and social isolation in people with HIV	24
A behavioral economics approach to enhancing HIV preexposure and postexposure prophylaxis implementation	23
Editorial introduction	22
Editorial introduction	19
Development of screening assays for use of broadly neutralizing antibodies in people with HIV	19
Persistent elite controllers as the key model to identify permanent HIV remission	18
Challenges towards an AIDS-free generation in Africa and Asia	18
Defining multimorbidity in people with HIV – what matters most?	17
The origins of new SARS-COV-2 variants in immunocompromised individuals	17
Fc-mediated immunological mechanisms in HIV infection: a better understanding for improved therapeutic approaches	17
Current insight into HIV-1 persistence from single-cell transcriptome profiling in acutely treated cohorts of infection	15
Viral and immune predictors of HIV posttreatment control	14
Balancing polypharmacy and comorbidity management: cardiovascular health	14

Role of follicular homing natural killer cells in HIV infection	13
Mpox and the impact on people with HIV	12
Impact of coronavirus disease 2019 on co-morbidities in HIV	12
The multifaceted nature of HIV tissue reservoirs	12
Editorial introduction	12
New vector and vaccine platforms: mRNA, DNA, viral vectors	12
Aging of adult lifetime survivors with perinatal HIV	12
Obesity among women with HIV	11
Broadly neutralizing antibodies for HIV treatment and cure approaches	11
Beyond criminalization: reconsidering HIV criminalization in an era of reform	11
Frailty in people with HIV: a geriatric syndrome approach to aging with HIV	11
Hepatitis co-infection in paediatric HIV: progressing treatment and prevention	11
Single-cell multiomic understanding of HIV-1 reservoir at epigenetic, transcriptional, and protein levels	11
Metabolic dysfunction-associated steatotic liver disease in people with HIV	11
Gender and sex considerations in HIV and bone health	10
Editorial: New drugs for HIV: quo vadis?	10
Host factors predisposing to kidney disease in people with HIV	10
HIV and cardiovascular disease: the role of inflammation	10
Strategies to target the central nervous system HIV reservoir	9
Single-cell sequencing technologies: a multiomics toolbox for investigating HIV-1 persistence	9
CD8+ T-cell responses in HIV controllers: potential implications for novel HIV remission strategies	9
Roadmap for spatial transcriptomics of HIV in tissues	9
Innovative models of care supporting people aging with HIV	9
The severity of COVID-19 across the spectrum of HIV	9
Editorial introduction	8
HIV drug resistance in various body compartments	8
Harnessing innate immunity: natural killer cells and innate immune responses in reservoir clearance	7
Guiding HIV-1 vaccine development with preclinical nonhuman primate research	7
Adolescents and young adults with HIV and unsuppressed viral load: where do we go from here?	7
Causes and outcomes of hepatic fibrosis in persons living with HIV	7
HIV-1 subtypes and latent reservoirs	7
Editorial: Is it time to implement injectable antiretroviral treatments globally?	7
Vaccinal effect of HIV-1 antibody therapy: dream or reality?	7
Persistent HIV-1 transcription during ART: time to reassess its significance?	7
Editorial introductions	7
Editorial introduction	7
Editorial introductions	7
Progress with induction of HIV broadly neutralizing antibodies in the Duke Consortia for HIV/AIDS Vaccine Development	6
HIV and comorbidities – the importance of gut inflammation and the kynurenine pathway	6
How could HIV-1 drug resistance impact preexposure prophylaxis for HIV prevention?	6
Whole person HIV services: a social science approach	6
Towards a molecular profile of antiretroviral therapy-free HIV remission	6
The pathogenesis of obesity in people living with HIV	6
The role of analytical treatment interruptions in shaping HIV-specific immunity and HIV cure	6
Towards an HIV cure: one cell at a time	6